293 related articles for article (PubMed ID: 27999019)
1. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity.
Yuste JR; Bertó J; Del Pozo JL; Leiva J
J Antimicrob Chemother; 2017 Feb; 72(2):625-628. PubMed ID: 27999019
[No Abstract] [Full Text] [Related]
2. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease.
Winthrop KL; Ku JH; Marras TK; Griffith DE; Daley CL; Olivier KN; Aksamit TR; Varley CD; Mackey K; Prevots DR
Eur Respir J; 2015 Apr; 45(4):1177-9. PubMed ID: 25614169
[No Abstract] [Full Text] [Related]
3. Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections.
Negatu DA; Aragaw WW; Cangialosi J; Dartois V; Dick T
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0165522. PubMed ID: 36920191
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection.
Murray MP; Laurenson IF; Hill AT
Clin Infect Dis; 2008 Jul; 47(2):222-4. PubMed ID: 18532890
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of non-tuberculous mycobacterial pleurisy with acute fever by antimycobacterial therapy.
Yamoto M; Kawagishi Y; Murata A; Tsuji H
BMJ Case Rep; 2018 Feb; 2018():. PubMed ID: 29437801
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment of atypical mycobacterial infections of the respiratory tract].
Andréjak C; Lescure FX; Schmit JL; Jounieaux V
Rev Mal Respir; 2011 Dec; 28(10):1293-309. PubMed ID: 22152937
[TBL] [Abstract][Full Text] [Related]
7. Linezolid for the treatment of patients with [corrected] mycobacterial infections [corrected] a systematic review.
Ntziora F; Falagas ME
Int J Tuberc Lung Dis; 2007 Jun; 11(6):606-11. PubMed ID: 17519090
[TBL] [Abstract][Full Text] [Related]
8. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
Ruth MM; Koeken VACM; Pennings LJ; Svensson EM; Wertheim HFL; Hoefsloot W; van Ingen J
J Antimicrob Chemother; 2020 Mar; 75(3):609-617. PubMed ID: 31886864
[TBL] [Abstract][Full Text] [Related]
9. [Ofloxacin in the treatment of pulmonary changes caused by Mycobacterium avium and Mycobacterium xenopii].
Zwoliński J; Gałazka J
Pneumonol Alergol Pol; 1992; 60(5-6):70-3. PubMed ID: 1290992
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Rodriguez Díaz JC; López M; Ruiz M; Royo G
Int J Antimicrob Agents; 2003 Jun; 21(6):585-8. PubMed ID: 12791475
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
[No Abstract] [Full Text] [Related]
12. [Lung diseases due to opportunistic environmental Mycobacteria in patients uninfected with human immunodeficiency virus. Risk factors, clinical and diagnostic aspects and course].
Martínez Moragón E; Menéndez R; Santos M; Lorente R; Marco V
Arch Bronconeumol; 1996 Apr; 32(4):170-5. PubMed ID: 8689013
[TBL] [Abstract][Full Text] [Related]
13. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.
Kwon YS; Daley CL; Koh WJ
Expert Rev Respir Med; 2019 Sep; 13(9):851-861. PubMed ID: 31256694
[No Abstract] [Full Text] [Related]
14. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long-term use of tedizolid after liver transplantation in an adolescent with pulmonary tuberculosis.
Yuste JR; Serrano-Alonso M; Carmona-Torre F; Del Pozo JL; Herrero JI
J Antimicrob Chemother; 2019 Sep; 74(9):2817-2819. PubMed ID: 31106345
[No Abstract] [Full Text] [Related]
16. Factors which influence treatment initiation for pulmonary non-tuberculous mycobacterium infection in HIV negative patients; a multicentre observational study.
Rawson TM; Abbara A; Kranzer K; Ritchie A; Milburn J; Brown T; Adeboyeku D; Buckley J; Davidson RN; Berry M; Kon OM; John L
Respir Med; 2016 Nov; 120():101-108. PubMed ID: 27817806
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic treatment for nontuberculous mycobacterial lung disease.
Kang YA; Koh WJ
Expert Rev Respir Med; 2016; 10(5):557-68. PubMed ID: 26967761
[TBL] [Abstract][Full Text] [Related]
18. New insights in the treatment of nontuberculous mycobacterial pulmonary disease.
Ruth MM; van Ingen J
Future Microbiol; 2017 Oct; 12():1109-1112. PubMed ID: 28972416
[No Abstract] [Full Text] [Related]
19. Mycobacterium triplex pulmonary disease with acquired macrolide resistance in immunocompetent patients.
Matsuda S; Suzuki S; Morimoto K; Aono A; Nishio K; Asakura T; Sasaki Y; Namkoong H; Nishimura T; Ogata H; Hasegawa N; Kurashima A; Ishii M; Tatsumi K; Mitarai S; Goto H
Clin Microbiol Infect; 2018 Jun; 24(6):671-672. PubMed ID: 29309938
[No Abstract] [Full Text] [Related]
20. Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects.
Seki M; Kamioka Y; Takano K; Imai H; Shoji M; Hariu M; Kabutoya Y; Watanabe Y
Am J Case Rep; 2020 Jun; 21():e924642. PubMed ID: 32598338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
